Connect with us

Cannabis News

Texas Judge Allows Smokable Hemp And Other Products To Be Sold, Blocking State Ban From Being Enforced

Published

2 months ago

on

A Texas judge has issued a temporary injunction that continues to prevent state officials from enforcing the news Regulations restricting access to hemp-derived products such as THCA combustible flower. Meanwhile, the state Supreme Court in a separate case allows regulators to ban delta-8 THC.

Friday’s ruling by Judge Daniella DeSeta Lyttle follows another judge last month who issued a temporary restraining order on the ban on hemp products. According to the latest order, sales of hemp products can continue until at least July 27.

Decisions a a lawsuit filed by a coalition of hemp industry leaders and advocacy organizations The Department of State Health Services (DSHS) and the Health and Human Services Commission (HHSC) have accused lawmakers of effectively circumventing the law. ban the sale and manufacture of certain hemp consumable products.

Under state law passed by the legislature and governor in 2019, the suit says cannabis products are legal if they contain no more than 0.3 percent delta-9 THC. But regulators at DSHS and HHSC recently approved a “total delta-9 THC” limit using a post-decarboxylation formula that includes tetrahydrocannabinolic acid (THCA) in the calculation.

Texas lawmakers passed legislation to severely restrict hemp products in the 2025 session, but Gov. Greg Abbott (R) vetoed it and did not make it into law.

Lyttle said Friday that the plaintiffs have established “a possible right to relief on the merits of their claims.”

“In the absence of injunction, plaintiffs will suffer immediate and continuing harm to their business operations, legal rights and economic interests,” he said. he wrote. “These damages include disruption of established supply chains, loss of market access, impairment of goodwill and customer relationships, and the risk of significant compliance costs and enforcement consequences under the rules that plaintiffs have proven invalid.”

The hemp industry lawsuit, which also lists Attorney General Ken Paxton (R) as a defendant, also calls into question large increases in business license fees that were approved by regulators. Under the new rules, the cost of a manufacturer’s license increased from $250 to $10,000 per facility, while the retailer registration fee increased from $150 to $5,000 per location.

While the judge who issued a temporary restraining order on the product restrictions last month did not grant a stay on the new fees, Lyttle included them within the scope of his temporary injunction.

“These measures do not impose policy choices of the Legislature; they supersede them,” says the initial complaint filed by plaintiffs Texas Hemp Business Council (THBC) and Hemp Industry & Farmers of America (HIFA). “And they do so against the backdrop of a constitutional legislative process that ran its entire course — from the legislative passage of Senate Bill 3 to the governor’s veto, two failed special sessions — and produced an ambiguous result: no new law. Texas law does not allow agencies to override that result through rulemaking.”

“Texas has long promoted itself as a national leader in economic growth and regulatory stability. It is a state committed to fostering innovation, supporting legitimate businesses, and maintaining a predictable legal environment in which businesses can operate and invest,” he says. “Consistent with that vision, Texas has chosen to authorize and regulate the manufacture, distribution and sale of consumable hemp products (‘CHP’) through a comprehensive statutory framework enacted by the Legislature in 2019.”

“Plaintiffs acknowledge this framework and the State’s interest in ensuring that CHPs are produced and sold in a safe, responsible and lawful manner,” the lawsuit states.

In a state Supreme Court ruling Friday, the justices overturned a lower court’s order that prevented regulators from treating delta-8 THC as a controlled substance.

“The companies that developed these products claim that the legislature opened up the market to them in 2019,” the court’s opinion says. “So when the commissioner sought to clarify that, in fact, the legislature had not clarified the potent levels of delta-8 THC manufactured in consumable hemp products, a group of businesses and consumers asked a court to rewrite the controlled substance schedules for him and the department, especially since the legislature legalized delta-8 THC in 2019 making the commissioner’s actions impossible and ultra vires.”

“The trial court granted that relief by way of a temporary injunction, which was affirmed by the appeals court. We now conclude that the lower courts exceeded their jurisdiction,” the justices said. find. “If the legislature wants to legalize powerful drugs, it has all the tools it needs to do so, and that is inevitable, as we expect such a big change in social policy. The role of the courts is simply to evaluate the state of the law as it stands.”

Separately, Texas officials conditionally approved more new medical marijuana business licenses As part of a law being implemented to significantly expand the state’s cannabis program.

A recent survey showed that Texas voters overwhelmingly support legalizing medical marijuana they still do not know, to a large extent, about the existing program.

in march Texas voters approved a question to legalize marijuana that showed up in the state’s Democratic primary voting.

Another statewide survey released in February found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the poll, many voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the poll. 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they had no opinion either way.

A separate survey released last year proved this Many Texas voters want the state’s marijuana laws to be “less strict.” And among the issues examined by members of parliament in the last special sessions, the voters said that a proposal to deal with the regulation of hemp was one of the least important.

Meanwhile, the lieutenant governor and speaker of the House recently announced that the state will continue with their own ibogaine research program The drug companies did not submit proposals to meet the requirements and standards for receiving state funds under a recently passed law to begin clinical trials with the psychedelic.

Image courtesy of AnonMoos.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Related Topics:
Continue Reading

Cannabis News

Massachusetts CCC pauses license applications

Published

7 hours ago

on

June 17, 2026

By











The Cannabis Control Commission, the government body that oversees the marijuana business in the state of Massachusetts (USA), has decided to temporarily stop accepting new license applications for growing marijuana, both indoors and outdoors. This hiatus officially began on June 16, 2026.

Anyone planning to apply for a new marijuana cultivation license after June 16, 2026 will not be able to do so while this suspension is in effect. The Commission will not accept such requests during this period.

There are two groups that can continue normally. First, anyone who submitted an application before June 16, 2026, will continue to review and process applications as usual. Second, applicants for specific programs designed to help communities historically affected by drug laws, known as the Social Equity Program and the Economic Empowerment Program, are exempt from this suspension if they apply for a smaller-scale “Microenterprise” license.

The suspension will be in effect for 120 days from June 16, 2026, which is currently scheduled to be lifted around mid-October 2026. However, the Commission has the power to terminate earlier or extend further, depending on market conditions.

Source: Massachusetts Cannabis Control Commission










Continue Reading

Cannabis News

Federal Marijuana Rescheduling ‘Does Not Appear To Apply’ To Washington Businesses, State Officials Say

Published

7 hours ago

on

June 17, 2026

By

Marijuana regulators in Washington say the Trump administration’s move to re-regulate cannabis at the federal level “doesn’t appear to apply” to the state’s businesses.

US Department of Justice in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA). A trial scheduled for this month will take place consider marijuana III.

“Washington does not issue licenses to producers, processors or retailers of medical cannabis,” the state’s Liquor and Cannabis Board (LCB) said in guidelines released Tuesday. “Instead, Washington has a single recreational market and within that market producers/processors can manufacture (DOH) compliant products, and certain retailers can sell DOH-compliant products to adult patients and all designated providers.”

“Therefore, Washington cannabis licensees do not appear to qualify as ‘state medical marijuana licensees’ and therefore may not be eligible for registration under the final Rule,” the agency said, referring to the Drug Enforcement Administration (DEA). Registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

That said, the LCB “does not take a position if licensees decide to apply for federal registration,” the guidance continues. “If a licensee is seeking federal registration, we would be interested in learning about their experience and federal decisions.”

However, “based on our analysis, the federal reorganization in its current form does not appear to apply to cannabis licensees in Washington, primarily because of the legal framework governing recreational cannabis,” the LCB said.

The agency emphasized, however, that while it has consulted with the Cannabis Regulatory Association, the National Governors Association and industry stakeholders, its current opinion does not represent Washington’s formal opinion and “may not be our final interpretation as information is evolving and the decision may not rest with the state.”

“We await additional guidance from the federal agencies involved, new or updated federal agency processes and/or other federal procedures,” he said. he saidreferring to the next administrative hearing and Ongoing litigation calls into question the rescheduling of cannabis.

“The LCB recognizes that there are many cannabis growers, processors, and retailers actively involved in the production and sale of medical cannabis in Washington. These businesses may or may not be eligible to use the 280e tax deduction, and may also register with the DEA III. Ultimately, they have no input into whether their licensees meet the criteria for “state medical marijuana licensees,” as that determination can be made unilaterally by the DOJ within the meaning of the Final Rule. to reasonably interpret and determine that Washington cannabis licensees qualify as “state medical marijuana licensees.”

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

In California, regulators recently approved emergency rule changes to the state’s marijuana licensing process. to make it easier for companies to receive benefits In line with the Trump administration’s latest move to federally regulate medical cannabis.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

How New Zealand showed up in London’s cannabis industry

Published

1 day ago

on

June 16, 2026

By

The medical cannabis market is expected to grow from $47 billion to $149 billion by 2031, and New Zealand has a real role to play in that story. And thanks in large part to New Zealand Trade and Enterprise (NZTE), the government’s international business development agency, Puro is starting to play.

At Cannabis Europa 2026 London, NZTE hosted an evening event at the City Arts Bar with Puro, New Zealand companies Bluelab, Rua Bioscience and CannFX. Puro called it The NZ Room.

Beyond all things Kiwiana – including Puro brand kiwifruit, Kiwi’d – the room was filled with some pretty amazing people: Ivy League scientists, company founders, patients, advocates, industry players, government officials, Maori tribal leaders and a tough Scotsman. All in the same space with the same true passion for where this industry is going.

It was one of those rooms where conversations went well when they had to end. That’s usually a sign of something well done.

Made possible by NZTE
For Puro, the NZTE relationship has been formative. With ongoing support, Puro has entered the Australian market with 47 unique product SKUs and signed a £7 million supply agreement with UK distributor IPS Pharma.

NZTE understands the potential of the New Zealand cannabis industry. The willingness to support this nascent industry and put New Zealand in the spotlight at events like Cannabis Europa is very significant. New Zealand is a small country and the country’s credibility in international markets is built from relationship to relationship, room by room. NZTE helps build those rooms.

© Cigar

what’s next
For the first time, patients in the UK have access to medicinal cannabis grown in New Zealand. That’s the direct result of years of work by Puro’s team, but it’s not worth much if you can’t connect with buyers globally. Creating international relationships that events like Cannabis Europa make this possible.

“We are grateful for the extensive support from the New Zealand Government that drives our progress, including the Ministry of Primary Industries’ support for our genetic breeding, product innovation and market access goals. This collective effort from agencies such as the Ministry of Business, Innovation and Employment, NZTE and the New Zealand Export Credit Bureau ensures that Mail that started in London will continue to grow in Puro’s international goals,” he said. a statement

For more information:
clean
www.puro.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media